Brazilian drugmaker Hypera plans to launch next year a generic version of semaglutide, the active ingredient of Novo ...

Q4 2023 Earnings Conference Call March 21, 2025 10:00 AM ETCompany ParticipantsBreno Toledo Pires de Oliveira - Chief ...

Hypera plans to introduce a generic version of semaglutide in Brazil following patent expiration in 2026. The company is optimistic about market growth despite potential price impacts. Analysts ...

Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Ascendis Pharma (ASND – Research Report) today and set a price target of $180.00. The company’s shares closed last Friday at ...

Zealand Pharma (ZLDPF) announced that the last participant has been enrolled and randomized to active treatment or placebo in ZUPREME-1, a global Phase 2b trial in people with obesity or ...

Innocan Pharma Ltd. Each Warrant is exercisable into one Common Share at a price of CAD$0.26 for a period of four (4) years from the date of issuance. Innocan intends to use the proceeds of the ...

Blog posts represent the views of CFR fellows and staff and not those of CFR, which takes no institutional positions. Most of the major U.S. pharmaceutical companies (AbbVie, Amgen, Bristol Myers ...

Produce high-quality, injectable drug delivery systems with the Thermo Scientific™ Pharma mini Implant Line. This automated end-to-end solution meets cGMP and FDA requirements. Accurate dosing ...

Trump last week said he was considering new duties of around 25% on pharmaceutical products, along with automobiles and semiconductors, as early as April. The tariff rates will "go very ...

SAN RAFAEL, Calif., Feb. 24, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has appointed Timothy P. Walbert, former chairman, president and ...

LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today announced an investment of over $6 million to expand its Rosenberg, Texas manufacturing ...

HERZLIYA, Israel and CALGARY, AB, Feb. 27, 2025 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased ...